Expertise in
27
conditions

Dr. Daniel J. Lee

Otolaryngology
Massachusetts Eye And Ear
243 Charles St, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Expertise in
27
conditions
Massachusetts Eye And Ear
243 Charles St, 
Boston, MA 

Overview

Daniel Lee is an Otolaryngologist practicing medicine in Boston, Massachusetts.

Dr. Lee is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Cholesteatoma, Acoustic Neuroma, Hearing Loss, Endoscopy, and Prostatectomy.

He is actively involved in clinical research, co-authoring 239 peer reviewed articles and participating in 14 clinical trials. Dr. Lee is currently accepting new patients.

Specialties

Otolaryngology

Licenses

Otolaryngology in MA

Hospital Affiliations

Massachusetts General Hospital
Massachusetts Eye And Ear Infirmary -
Brigham And Women's Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Massachusetts Eye and Ear
243 Charles St, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Evaluating Effectiveness of Home Testing Devises for Assisting in Management of Glaucoma Outside a Clinical Setting During a 2 Year Period.
Evaluating Effectiveness of Home Testing Devises for Assisting in Management of Glaucoma Outside a Clinical Setting During a 2 Year Period.
Enrollment Status: Completed
Publish Date: August 20, 2026
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Olaparib, Radium-223
Study Phase: Phase 1/Phase 2
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer
A Phase 2 Study of M6620 (VX-970, Berzosertib) in Combination With Carboplatin Compared With Docetaxel in Combination With Carboplatin in Metastatic Castration-Resistant Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Other
Study Drugs: Berzosertib, Carboplatin, Docetaxel
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria
Enrollment Status: Terminated
Publish Date: January 13, 2026
Intervention Type: Drug
Study Drugs: MBG453, Hypomethylating agents
Study Phase: Phase 2
A Prospective Randomized Controlled Trial of GlaucoCetin vs Placebo in Glaucoma Patients With Visual Field Loss.
A Prospective Randomized Controlled Trial of GlaucoCetin vs Placebo in Glaucoma Patients With Visual Field Loss.
Enrollment Status: Terminated
Publish Date: December 23, 2025
Intervention Type: Dietary supplement, Other
Study Phase: Not Applicable
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Enrollment Status: Terminated
Publish Date: January 17, 2025
Intervention Type: Drug
Study Drugs: Magrolimab, Azacitidine
Study Phase: Phase 1
Using Patient Centered Data and Behavioral Economics to Improve Mobility and Reduce Readmissions After Major Abdominal Surgery for Cancer
Using Patient Centered Data and Behavioral Economics to Improve Mobility and Reduce Readmissions After Major Abdominal Surgery for Cancer
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Behavioral
Study Phase: Not Applicable
A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Completed
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 1
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Phase 2, Randomized, Biomarker-driven Clinical Study in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With MCL-1 Dependence ≥30%
Enrollment Status: Terminated
Publish Date: November 15, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
A Phase 2, Open-label, Randomized, Two-stage Clinical Study of Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia Following Treatment With Venetoclax Combination Therapy
Enrollment Status: Terminated
Publish Date: November 09, 2023
Intervention Type: Drug
Study Drugs: Alvocidib, Cytarabine
Study Phase: Phase 2
View 9 Less Clinical Trials

239 Total Publications

Bradycardia in the emergency department: quality measures and opportunities for improvement.
Bradycardia in the emergency department: quality measures and opportunities for improvement.
Journal: The American journal of emergency medicine
Published: July 07, 2026
Similar Doctors
Expertise in
34
conditions
Dr. Daniel G. Deschler
Otolaryngology | Plastic Surgery
Expertise in
34
conditions
Dr. Daniel G. Deschler
Otolaryngology | Plastic Surgery
Referral may be required

Office

243 Charles St Fl 2, 
Boston, MA 
 (0.1 miles away)
617-573-4100
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Daniel Deschler is an Otolaryngologist and a Plastic Surgeon practicing medicine in Boston, Massachusetts. Dr. Deschler is highly rated in 34 conditions, according to our data. His clinical expertise encompasses Salivary Gland Tumors, Acinic Cell Carcinoma of Salivary Glands, Tongue Cancer, Laryngectomy, and Glossectomy. Dr. Deschler is currently accepting new patients.

Expertise in
23
conditions
Dr. Stacey T. Gray
Otolaryngology
Expertise in
23
conditions
Dr. Stacey T. Gray
Otolaryngology
Referral may be required

Massachusetts Eye And Ear

243 Charles St, 
Boston, MA 
 (0.1 miles away)
617-573-4188
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Stacey Gray is an Otolaryngologist practicing medicine in Boston, Massachusetts. Dr. Gray is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Sinusitis, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), Nasal Polyps, Septoplasty, and Balloon Sinuplasty. Dr. Gray is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Massachusetts Eye And Ear

243 Charles St, 
Boston, MA 
 (0.1 miles away)
617-573-3972
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Konstantina Stankovic is an Otolaryngologist practicing medicine in Boston, Massachusetts. Dr. Stankovic is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Schwannoma, Acoustic Neuroma, Hearing Loss, Tinnitus, and Myringotomy.

Frequently Asked Questions about Dr. Daniel J. Lee

How do I make an appointment with Dr. Daniel J. Lee?

You can book an appointment with Dr. Daniel J. Lee by calling their office at 617-573-3130. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel J. Lee a top-rated expert for Cholesteatoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel J. Lee is classified as an Elite expert for Cholesteatoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel J. Lee specialize in?

While Dr. Daniel J. Lee is a Otolaryngology, they have specific expertise in Cholesteatoma, Acoustic Neuroma, and Hearing Loss. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Otolaryngology.

Does Dr. Daniel J. Lee participate in research or clinical trials?

Yes. Dr. Daniel J. Lee has published 239 articles and abstracts on conditions like Cholesteatoma. You can view a list of Dr. Daniel J. Lee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel J. Lee accept my insurance?

Dr. Daniel J. Lee accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 617-573-3130 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lee's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 16 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile